Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
James Bradner
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Tensha Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This research involves the investigation and alteration of the chemical structure of a bromodomain inhibitor (JQ1) which was developed in the Bradner laboratory. Tensha Therapeutics holds an exclusive license to develop and commercialize the compound, while Dana-Farber Cancer Institute retains the right to conduct further research on the compound. A reasonable person could conclude that the outcome of this research could directly and significantly affect the financial interest of Tensha Therapeutics.
Selective inhibition of BRDT for male contraception
RELEVANCE (See instrudions): The proposed research will convincingly advance basic scientific knowledge and is poised to contribute significantly to public health through the creation of novel male contraceptives that are potent and selective inhibitors of the male germ cell specific protein BRDT. Our data is the first to identify a drug that functions as a reversible contraceptive through its actions on the male germline. This research will also nucleate an interdisciplinary team of scientific investigators with complimentary expertise in chemistry, biochemistry, cell biology, developmental biology and fertility toward the common goal of developing a male contraceptive pill.
Filed on March 08, 2013.
Tell us what you know about James Bradner's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
James Bradner filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| James Bradner | Dana Farber Cancer Inst | Conflict of Interest | Tensha Therapeutics | $100,000 - $149,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.